Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
暂无分享,去创建一个
[1] Lucio Crinò,et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. Ou,et al. Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management. , 2015, Lung cancer.
[3] M. McTigue,et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations , 2015, Proceedings of the National Academy of Sciences.
[4] Caicun Zhou,et al. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer. , 2015, Clinical lung cancer.
[5] P. Brastianos,et al. Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[7] J. Neal,et al. Review of the current targeted therapies for non-small-cell lung cancer. , 2014, World journal of clinical oncology.
[8] B. Besse,et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Hiroshi Sakamoto,et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases , 2014, Cancer Chemotherapy and Pharmacology.
[10] Ruey-min Lee,et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. , 2014, The Lancet. Oncology.
[11] A. Shaw,et al. 1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] K. Okuno,et al. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition , 2014, International journal of oncology.
[13] Wei Liu,et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos , 2014, Journal of medicinal chemistry.
[14] F. Khuri,et al. Second-generation ALK inhibitors: filling the non "MET" gap. , 2014, Cancer discovery.
[15] T. Clackson,et al. Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). , 2014 .
[16] Michael Thomas,et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. , 2014 .
[17] Makoto Nishio,et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. , 2014, Cancer discovery.
[18] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[19] P. Jänne,et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Susan M. Chang,et al. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. , 2013, The Lancet. Oncology.
[21] Susan M. Chang,et al. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. , 2013, The Lancet. Oncology.
[22] Sungjoon Kim,et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 , 2013, Journal of medicinal chemistry.
[23] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[24] C. Marosi,et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. , 2013, Lung cancer.
[25] Y. Ohe,et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. , 2013, The Lancet. Oncology.
[26] P. Bunn,et al. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[27] A. Iafrate,et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. , 2012, The oncologist.
[28] Jeffrey W. Clark,et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.
[29] A. Shaw,et al. Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. , 2012 .
[30] H. Sakamoto,et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). , 2012, Bioorganic & medicinal chemistry.
[31] Yuichi Sugiyama,et al. Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a Surrogate , 2011, Journal of Pharmacology and Experimental Therapeutics.
[32] S. Ou. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond , 2011, Drug design, development and therapy.
[33] S. Kobayashi,et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Hiroshi Sakamoto,et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. , 2011, Cancer cell.
[35] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[36] B. Yeap,et al. Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib , 2010, Clinical Cancer Research.
[37] Jeffrey W. Clark,et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. , 2010 .
[38] T. Clackson,et al. Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066) , 2010 .
[39] Juan J. Miret,et al. Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK) , 2010 .
[40] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] A. Iafrate,et al. Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population , 2009, Clinical Cancer Research.
[42] K. Lyons,et al. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[43] T. Clackson,et al. Abstract #3738: Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK) , 2009 .
[44] Dieta Brandsma,et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.
[45] A. Iafrate,et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.
[46] Yuki Togashi,et al. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[47] Shinji Yamazaki,et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.
[48] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[49] Shinji Yamazaki,et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.